| Title |
Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
|
|---|---|
| Published in |
Investigational New Drugs, July 2013
|
| DOI | 10.1007/s10637-013-9988-x |
| Pubmed ID | |
| Authors |
Patricia LoRusso, Karthik Venkatakrishnan, E. Gabriela Chiorean, Dennis Noe, Jing-Tao Wu, Serap Sankoh, Maria Corvez, Edward A. Sausville |
| Abstract |
This phase 1 study assessed safety, maximum tolerated dose (MTD), pharmacokinetics, cerebrospinal fluid (CSF) distribution, and preliminary clinical activity of the receptor tyrosine kinase inhibitor TAK-285. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 21% |
| Student > Bachelor | 7 | 21% |
| Student > Ph. D. Student | 5 | 15% |
| Student > Postgraduate | 3 | 9% |
| Student > Doctoral Student | 2 | 6% |
| Other | 5 | 15% |
| Unknown | 5 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 26% |
| Biochemistry, Genetics and Molecular Biology | 4 | 12% |
| Psychology | 4 | 12% |
| Business, Management and Accounting | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Other | 7 | 21% |
| Unknown | 6 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 November 2013.
All research outputs
#18,355,685
of 22,733,113 outputs
Outputs from Investigational New Drugs
#876
of 1,167 outputs
Outputs of similar age
#145,920
of 194,378 outputs
Outputs of similar age from Investigational New Drugs
#10
of 12 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,167 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,378 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.